Cancer Immunotherapy

Cancer Immunotherapy
Author: Saul J. Priceman
Publisher: Elsevier Inc. Chapters
Total Pages: 33
Release: 2013-06-04
Genre: Medical
ISBN: 0128059222

Tumor-associated immune cells, in particular myeloid cells, have opposing roles during cancer development by facilitating antitumor immune responses and driving cancer-promoting inflammation. Defective antitumor immunity is prevalent in cancers, and it is now clear that overcoming the myeloid cell-mediated immunosuppressive microenvironment poses tremendous interest for future cancer therapies. JAK/STAT signaling has come to the forefront as a crucial pathway to induce immunosuppression and procancer inflammation. Specifically, STAT3 activation is critical for the phenotype of myeloid cells by regulating immunosuppressive and prometastatic factors, thereby providing myeloid cells with a multitude of tumor-promoting functions. Genetic ablation of STAT3 in the myeloid compartment induces potent innate and adaptive antitumor immunity along with an inhibition of tumor growth and metastasis. Recently, therapeutic targeting of JAK/STAT3 has shown great promise in blocking immunosuppression in preclinical models. One such example is the use of novel siRNA to selectively target STAT3 in myeloid cells, through conjugation to CpG oligonucleotides that agonize Toll receptor TLR9 on myeloid cells. Along with other novel therapeutic strategies to inhibit JAK/STAT signaling, it seems likely that future efforts to target this pathway will be made in single and combination approaches for effective anticancer immunotherapy.

Myeloid-Derived Suppressor Cells and Cancer

Myeloid-Derived Suppressor Cells and Cancer
Author: David Escors
Publisher: Springer
Total Pages: 109
Release: 2016-03-15
Genre: Medical
ISBN: 331926821X

The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.

Enhancing Immune Therapy for Cancer by Targeting Myeloid Derived Suppressor Cells

Enhancing Immune Therapy for Cancer by Targeting Myeloid Derived Suppressor Cells
Author: Andrew Robert Stiff
Publisher:
Total Pages:
Release: 2017
Genre: Immune system
ISBN:

While some of the mechanisms that cause impaired NK cell and T cell function are linked to processes inherent to tumor cells such as cytokine production and metabolic alterations it is also clear that cancer is linked to the expansion of multiple immune suppressive cell populations such as regulatory T cells (Treg), tumor associated macrophages (TAMs), and myeloid derived suppressor cells (MDSC).

Immuno-Oncology Crosstalk and Metabolism

Immuno-Oncology Crosstalk and Metabolism
Author: Muzafar Ahmad Macha
Publisher: Springer Nature
Total Pages: 223
Release: 2022-05-16
Genre: Medical
ISBN: 9811662266

This book discusses the novel metabolic cross-talk between immune and tumor cells in the tumor microenvironment that promotes their growth and progression. It also describes deregulated metabolism in cancer cells that promotes suppressive and cancer cell-favourable microenvironment. Further, the book provides novel insights on the metabolic changes in immune cells that promote tumor cell growth and survival. In turn, it also reviews the involvement of immuno-onco metabolic cross-talk in the development of resistance to chemo-radiation therapy (CRT) in tumor cells. Lastly, it also explores the potential of immuno-oncology metabolism as a therapeutic approach against tumor cells.

Cancer Immunotherapy

Cancer Immunotherapy
Author: George C. Prendergast
Publisher: Academic Press
Total Pages: 679
Release: 2013-06-04
Genre: Medical
ISBN: 0123946336

There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer, and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumor immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers with an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease. Offers a synthesis of concepts that are useful to cancer immunologists and pharmacologists, who tend to work in disparate fields with little cross-communication Drs. Prendergast and Jaffee are internationally recognized leaders in cancer biology and immunology who have created a unique synthesis of fundamental and applied concepts in this important new area of cancer research Summarizes the latest insights into how immune escape defines an essential trait of cancer Includes numerous illustrations, including how molecular-targeted therapeutic drugs or traditional chemotherapy can be combined with immunotherapy to improve anti-tumor efficacy and how reversing immune suppression by the tumor can cause tumor regression